These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 20092424

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL.
    Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
    Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L.
    Cancer Immun; 2007 Mar 09; 7():6. PubMed ID: 17346028
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK.
    Clin Cancer Res; 2015 Jan 15; 21(2):448-59. PubMed ID: 25416196
    [Abstract] [Full Text] [Related]

  • 12. Clinical trials and future potential of targeted therapy for ovarian cancer.
    Itamochi H, Kigawa J.
    Int J Clin Oncol; 2012 Oct 15; 17(5):430-40. PubMed ID: 22926640
    [Abstract] [Full Text] [Related]

  • 13. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.
    Kristjansdottir K, Dizon D.
    Expert Opin Biol Ther; 2010 Feb 15; 10(2):243-50. PubMed ID: 20001562
    [Abstract] [Full Text] [Related]

  • 14. Profile of farletuzumab and its potential in the treatment of solid tumors.
    Sato S, Itamochi H.
    Onco Targets Ther; 2016 Feb 15; 9():1181-8. PubMed ID: 27022278
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
    Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O'Shannessy D, Herzog TJ.
    J Clin Oncol; 2016 Jul 01; 34(19):2271-8. PubMed ID: 27001568
    [Abstract] [Full Text] [Related]

  • 17. Pertuzumab for the treatment of ovarian cancer.
    Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ.
    Expert Opin Biol Ther; 2010 Jul 01; 10(7):1113-20. PubMed ID: 20465533
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.